News from takeda pharmaceuticals u.s.a., inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 28, 2019, 09:05 ET First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes: Takeda's Investigational Therapy Meets Co-Primary & Key Secondary Efficacy Endpoints

Takeda Pharmaceuticals U.S.A., Inc., ("Takeda") (TSE:4502/NYSE:TAK) announced today that Budesonide Oral Suspension (BOS), its investigational...

May 17, 2019, 08:04 ET U.S. FDA Approves GATTEX® (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)

Takeda Pharmaceuticals, U.S.A., Inc. ("Takeda"), announced today that the U.S. Food and Drug Administration (FDA) approved extending the indication...

Apr 02, 2019, 08:00 ET Motegrity™ (prucalopride), the Only Serotonin-4 Receptor Agonist for Adults with Chronic Idiopathic Constipation (CIC), is Now Available in the United States

Takeda Pharmaceuticals U.S.A., Inc., ("Takeda") today announced that Motegrity™ (prucalopride), a once-daily, oral treatment option, is now...

Oct 08, 2018, 08:00 ET New Real-World Data Analyses Support the Long-Term Use of Entyvio® (vedolizumab) in Bio-Naïve Patients for the Treatment of Moderate to Severe Ulcerative Colitis or Crohn's Disease

Takeda Pharmaceuticals U.S.A., Inc., ("Takeda") today announced the presentation of new long-term efficacy real-world data analyses for Entyvio®...

Nov 20, 2017, 07:32 ET Takeda et Cognition Kit présentent les résultats d'une étude faisant appel à la technologie numérique vestimentaire chez des patients atteints d'un trouble dépressif majeur (TDM)

Aujourd'hui, Takeda et Cognition Kit ont annoncé qu'elles présenteraient les résultats de MDD-5003, une étude pilote visant à examiner les données...

Nov 20, 2017, 06:18 ET Takeda und Cognition Kit präsentieren Ergebnisse der Studie zu digitaler Wearable-Technologie bei Patienten mit schweren depressiven Störungen (MDD)

Takeda und Cognition Kit gaben heute bekannt, dass die Unternehmen die Ergebnisse aus der Studie MDD-5003 während des 2017 CNS Summit Meeting in Boca ...

Nov 20, 2017, 05:25 ET Takeda y Cognition Kit presentan un estudio sobre tecnología digital ponible en pacientes de trastorno depresivo mayor

Takeda y Cognition Kit han anunciado hoy que ambas empresas van a presentar los resultados del MDD-5003, un estudio piloto diseñado para evaluar los...

Nov 19, 2017, 06:07 ET Společnosti Takeda a Cognition Kit představily výsledky studie digitální přenosné technologie u pacientů s depresivní poruchou (MDD)

Společnosti Takeda a Cognition Kit dnes oznámily, že výsledky pilotního projektu MDD-5003, který měl vyhodnotit kognitivní funkce u pacientů s...

Nov 18, 2017, 02:18 ET Takeda i Cognition Kit publikują wyniki badań nad wykorzystaniem cyfrowych urządzeń ubieralnych u pacjentów z ciężkimi zaburzeniami depresyjnymi

Firmy Takeda i Cognition Kit ogłosiły dziś, że w trakcie szczytu CNS 2017 w Boca Raton w stanie Floryda, który odbędzie się w dniach 16-19 listopada...

Nov 17, 2017, 17:11 ET Spoločnosti Takeda a Cognition Kit predstavujú výsledky štúdie digitálnej nositeľnej technológie u pacientov s epizódami ťažkej depresie (MDD)

Spoločnosti Takeda a Cognition Kit dnes oznámili, že počas vrcholného stretnutia CNS 2017 v Boca Raton na Floride, ktoré sa bude konať od 16. do 19....

Nov 17, 2017, 15:01 ET Takeda и Cognition Kit представляют результаты исследования эффективности применения носимых технологий у пациентов с большим депрессивным расстройством

Takeda и Cognition Kit сегодня сообщили о предстоящей совместной презентации результатов MDD-5003 - пилотного исследования, ориентированного на...

Nov 17, 2017, 12:57 ET Takeda and Cognition Kit Present Results from Digital Wearable Technology Study in patients with Major Depressive Disorder (MDD)

Takeda and Cognition Kit today announced that the companies will present results from MDD-5003, a pilot study to evaluate cognitive and mood...

Nov 17, 2017, 08:00 ET The Boston Globe Names Takeda Pharmaceuticals U.S.A., Inc. a Top Place to Work for 2017

Takeda Pharmaceuticals U.S.A., Inc. has been named by The Boston Globe as one of its 2017 Top Places to Work. Each year, the outlet partners with...

Nov 10, 2017, 11:35 ET The Chicago Tribune Names Takeda Pharmaceuticals U.S.A., Inc. A Workplace Achiever of the Chicago Area 2017 Top Workplaces Award

Takeda Pharmaceuticals U.S.A., Inc. has been awarded a 2017 Top Workplaces, Workplace Achiever honor by The Chicago Tribune. The Top Workplaces lists ...

Oct 06, 2017, 13:57 ET Takeda Donates $100,000 to Local, Regional Charities as Part of Company's Takeda Cares Day Event

Takeda Pharmaceuticals U.S.A., Inc. announced today that it will donate $100,000 to local and regional nonprofits as part of its annual corporate...

Oct 04, 2017, 16:08 ET Takeda Welcomes The Honorable Susana Mendoza As Guest Speaker At Deerfield Headquarters To Celebrate Company's Commitment to Latino Culture

Takeda Pharmaceuticals U.S.A., Inc. welcomed the Honorable Susana Mendoza, State of Illinois Comptroller, to its corporate offices in Deerfield today ...

Mar 17, 2017, 10:54 ET Takeda Receives Award for Supporting Employees Who Serve In Military

Takeda Pharmaceuticals U.S.A., Inc. received an award from the Illinois Committee of the Employer Support of the Guard and Reserve (ESGR) during a...

Feb 24, 2017, 03:28 ET Takeda y Cognition Kit se asocian en un estudio piloto de software que se puede llevar

Takeda Pharmaceuticals U.S.A., Inc., una filial de propiedad completa de Takeda Pharmaceutical Company Limited (TSE:4502), y Cognition Kit Limited,...

Feb 23, 2017, 19:21 ET Takeda i Cognition Kit współpracują przy pilotażowym zastosowaniu oprogramowania na urządzenie ubieralne u pacjentów z ciężkimi zaburzeniami depresyjnymi

Firma Takeda Pharmaceuticals U.S.A., Inc. pozostająca w pełnym posiadaniu Takeda Pharmaceutical Company Limited (TSE:4502) oraz Cognition Kit...

Feb 23, 2017, 19:05 ET Společnosti Takeda a Cognition Kit budou společně testovat nositelný software u pacientů s velkou depresivní poruchou (MDD)

Takeda Pharmaceuticals U.S.A., Inc., plně vlastněná dceřiná společnost společnosti Takeda Pharmaceutical Company Limited (TSE:4502), a Cognition Kit...

Feb 23, 2017, 12:44 ET Spoločnosti Takeda a Cognition Kit spájajú svoje sily pri realizácii pilotnej štúdie s nositeľným softvérom pre pacientov s epizódami ťažkej depresie

Spoločnosti Takeda Pharmaceuticals U.S.A., Inc., dcérska spoločnosť v úplnom vlastníctve firmy Takeda Pharmaceutical Company Limited (TSE:4502) a...

Feb 23, 2017, 07:07 ET Takeda et Cognition Kit établissent un partenariat afin de tester un logiciel portable pour les patients atteints de dépression caractérisée

Takeda Pharmaceuticals U.S.A., Inc., une filiale détenue à 100 % par Takeda Pharmaceutical Company Limited (TSE : 4502) et Cognition Kit Limited, une ...

Feb 23, 2017, 04:42 ET Takeda und Cognition Kit gehen Studienpartnerschaft für Erstanwendung von tragbarer Software in Patienten mit schwerer depressiver Störung (MDD) ein

Takeda Pharmaceuticals U.S.A., Inc., eine hundertprozentige Tochtergesellschaft von Takeda Pharmaceutical Company Limited (TSE:4502), und Cognition...

Feb 23, 2017, 04:01 ET Takeda и Cognition Kit будут совместно разрабатывать носимое программное обеспечение для пациентов, страдающих клинической депрессией (MDD)

Takeda Pharmaceuticals U.S.A., Inc., стопроцентное дочернее предприятие Takeda Pharmaceutical Company Limited (TSE:4502) и Cognition Kit Limited,...

Feb 23, 2017, 01:05 ET Takeda and Cognition Kit partner in study to pilot wearable software in patients with Major Depressive Disorder (MDD)

Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Cognition Kit Limited, a joint ...